Huawei Watch GT 6 Pro Adds Diabetes Risk Screening Feature

Huawei has become the first major smartwatch brand to ship active diabetes risk screening on a consumer wrist device, built into the Watch GT 6 Pro. This is not a glucose monitor. It is a risk-flagging tool, using optical PPG sensors to analyze blood volume pulse patterns and derive vascular health indicators associated with elevated blood sugar risk. The timing matters: Garmin, Apple, and Samsung all hold patents in this space, with analyst consensus pointing to 2026-2027 product releases.

How the Sensor Tech Actually Works

The Watch GT 6 Pro uses an optical PPG array, the same light-based blood volume sensing tech found on every modern sport watch from the Garmin Fenix 8 to the Polar Vantage V3. It is not measuring blood glucose directly. No consumer wrist wearable can do that yet without a separate sensor patch. What Huawei's algorithm does is cross-reference PPG waveform morphology, heart rate variability, and SpO2 readings (also optical) to build a risk profile. Think of it as pattern recognition, not a blood test. The screening requires a dedicated measurement session, not passive always-on monitoring.

This distinction matters a lot for endurance athletes. Your HRV and SpO2 patterns shift dramatically after a hard 20km run or a two-hour cycling interval session. Post-exercise optical readings are notoriously noisy. Huawei says the algorithm filters for exercise-induced variation, but independent validation data on athletes specifically is not yet published. Polar's OHR lab has documented how intense training sessions create PPG artifacts that fool even the best algorithms, so skepticism here is reasonable.

Garmin, Apple, and Samsung: Where They Stand

Garmin filed patents in 2024 covering non-invasive glucose estimation using multi-wavelength optical sensors combined with skin temperature and electrodermal activity. Apple's patent portfolio goes further, with near-infrared spectroscopy approaches that would require hardware not yet in any Apple Watch Series. Samsung's Galaxy Watch patents describe a hybrid approach pairing optical and bioelectrical impedance sensors. None of these are shipping in 2026 as finished diabetes screening tools. Huawei is genuinely first to market at scale.

For comparison, Whoop 5.0 currently tracks HRV, respiratory rate, and skin temperature but makes no metabolic disease risk claims. The Coros Vertix 3 focuses on training load and altitude acclimatization. The Garmin Fenix 8 Solar has blood oxygen via SpO2 and advanced HRV tracking, but Garmin has been careful not to position any of this as clinical screening. Huawei is taking the boldest public health positioning of any wearable brand right now, which will invite regulatory scrutiny in Europe and North America.

What This Means for Endurance Athletes

Most triathletes, runners, and cyclists reading this are probably thinking: I am fit, I train 10-plus hours a week, why does diabetes risk screening apply to me? Fair question. But Type 2 diabetes risk is not purely a sedentary person's problem. High training volume combined with poor carbohydrate management, chronic sleep debt, and overtraining syndrome can impair insulin sensitivity over time. Whoop has published internal data showing that athletes with high strain and poor recovery scores show HRV suppression patterns consistent with metabolic stress. A wrist-based early warning flag, even an imperfect one, has genuine value if it prompts a proper blood panel.

For Hyrox and CrossFit athletes specifically, body composition shifts and high-glycemic fueling strategies make metabolic health monitoring more relevant than in purely aerobic sports. A tool that flags elevated risk and says get a fasting glucose test is more useful than nothing. The key word is flag, not diagnose. Huawei's own documentation uses the word screening, not diagnosis, which is the correct framing.

What Is Missing or Disappointing

The biggest gap right now is peer-reviewed clinical validation specifically in trained athletes. Huawei published data in partnership with a Chinese hospital network, but the sample was predominantly sedentary adults over 40. That is a completely different physiological context from a 35-year-old running 70km per week. There is also no open API for the diabetes risk data, so it stays locked in the Huawei Health app with no export to platforms like Training Peaks or Garmin Connect. The Watch GT 6 Pro itself lacks the third-party app ecosystem that makes Garmin or Apple Watch useful as all-in-one training tools. Battery life is excellent at around 14 days in smart mode, but the GPS accuracy on long runs still trails the Fenix 8 and Coros Vertix 3 in dense urban environments.

The diabetes screening feature is also limited to specific markets at launch, with regulatory clearance in the EU and US still pending. If you buy this watch today in North America, you may not have access to the flagship feature that justifies the premium.

This watch makes most sense for athletes who are also managing family history of Type 2 diabetes or who want a single device that covers both serious training metrics and broader health monitoring. At roughly the same price point as a Garmin Forerunner 965, the GT 6 Pro trades a richer training ecosystem and superior third-party app support for genuinely novel health screening capabilities. If training performance is your primary concern, the Fenix 8 or Coros Vertix 3 remain stronger choices. If metabolic health monitoring is something you actually want to track alongside your training, Huawei just moved ahead of everyone else.